SAB Biotherapeutics
SABS
38 hedge funds and large institutions have $3.28M invested in SAB Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 5 closing their positions.
92% more capital invested
Capital invested by funds: $1.71M → $3.28M (+$1.58M)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.02% more ownership
Funds ownership: 0.77% → 0.79% (+0.02%)
3% less funds holding
Funds holding: 39 → 38 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$214K |
| 2 |
Renaissance Technologies
New York
|
+$44.6K |
| 3 |
PGFC
Peapack-Gladstone Financial Corp
Bedminster,
New Jersey
|
+$42.8K |
| 4 |
IFAM
Institutional & Family Asset Management
Fort Collins,
Colorado
|
+$34.6K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$78.2K |
| 2 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$59.2K |
| 3 |
BlackRock
New York
|
-$47K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$12.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.94K |
SABS Hedge Fund Activity: Q2 2023 in Review
38 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2023, worth a combined $3.28M — up 92% from $1.71M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SABS and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $214K. The largest seller was Warberg Asset Management, exiting entirely with an estimated $78.2K sold.
- 38 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2023, down from 39 in Q1 2023.
- Funds reported $3.28M of SAB Biotherapeutics stock for Q2 2023, up 92% quarter-over-quarter.
- 4 funds opened new SAB Biotherapeutics positions in Q2 2023 and 5 closed out, a net change of -1 holder.
- The largest SAB Biotherapeutics buyer in Q2 2023 was Vanguard Group, an estimated $214K added.
- The largest SAB Biotherapeutics seller in Q2 2023 was Warberg Asset Management, an estimated $78.2K sold.
Based on aggregated 13F filings for Q2 2023.